The mechanisms of action of PPARs

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 409-435

  Berger, Joel ^a   Moller, David E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Diabetes; Dyslipidemia; Nuclear receptors; PPAR

Indexed keywords

2 CHLORO 3 [4 (2 METHYL 2 PHENYLPROPOXY)PHENYL]PROPIONIC ACID ETHYL ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ANTILIPEMIC AGENT; CIGLITAZONE; CLOFIBRATE; ENGLITAZONE; FATTY ACID; FENOPROFEN; FIBRIC ACID DERIVATIVE; GW 0072; GW 2570; IBUPROFEN; ICOSANOID; INDOMETACIN; L 796449; L 805645; LIGAND; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLACETIC ACID DERIVATIVE; PIOGLITAZONE; RETINOID X RECEPTOR; ROSIGLITAZONE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASSAY; ATHEROSCLEROSIS; CANCER; CENTRAL NERVOUS SYSTEM; CRYSTAL STRUCTURE; DEMYELINATION; DIABETES MELLITUS; DIMERIZATION; DNA RESPONSIVE ELEMENT; DRUG EFFECT; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; FERTILITY; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; HYPERTENSION; IN VIVO STUDY; INFERTILITY; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MOLECULAR CLONING; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; REVIEW; TRANSCRIPTION INITIATION; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0036183630     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.104018     Document Type: Review

References (183)

1. Evolution of the nuclear receptor gene superfamily
2. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
3. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
4. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARγ). Differential activity of PPARγ 1 and -2 isoforms and influence of insulin
5. The peroxisome proliferator-activated receptor interacts with the retinoid X receptor in vivo
6. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid
7. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
8. Peroxisome proliferator activated receptors: Transcriptional regulators of adipogenesis, lipid metabolism and more
9. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element
10. Coactivator and corepressor complexes in nuclear receptor function
11. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
12. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
13. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: Binding and activation correlate with antidiabetic actions in db/db mice
14. Cloning and identification of mouse steroid receptor coactivator- 1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma
15. Isolation characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor
16. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis
17. Receptor-interacting protein 140 interacts with and inhibits transactivation by peroxisome proliferator-activated receptor alpha and liver-X-receptor alpha
18. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma
19. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation
20. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ
21. Novel PPARγ and PPARδ ligands produce distinct biological effects
22. L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding
23. Nuclear receptors have distinct affinities for coactivators: Characterization by fluorescence resonance energy transfer
24. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
25. 15-Deoxy-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
26. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
27. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists
28. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor
29. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
30. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ
31. Differential activation of peroxisome proliferator-activated receptors by eicosanoids
32. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes
33. Enhancement of adipocyte differentiation by an insulin-sensitizing agent
34. Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene
35. mPPARgamma 2: Tissue-specific regulator of an adipocyte enhancer
36. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones
37. Peroxisome proliferator-activated receptor (PPAR) γ agonists for diabetes
38. The PPARs: From orphan receptors to drug discovery
39. Hypoglycemic activity of a series of alpha-alkylthio and alpha-alkoxy carboxylic acids related to ciglitazone
40. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats
41. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity
42. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
43. Modification and distribution of lipids by ethylchlorophenoxyisobutyrate
44. Nature of hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat
45. Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library
46. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity
47. Activation of PPARδ alters lipid metaboism in db/db mice
48. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
49. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors
50. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: Expression in hematopoietic cells and chromosomal mapping
51. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: Alternative promoter use and different splicing yield two mPPARγ isoforms
52. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma1 and gamma2
53. The organization, promoter analysis, and expression of the human PPARgamma gene
54. Adipocyte-specific transcription factor ARF 6 is a heterodimeric complex of two nuclear hormone receptors, PPARg and RXRa
55. Stimulation of adipogenesis in fibroblasts by PPARγ 2, a lipid activated transcription factor
56. PPARγ is required for placental, cardiac, and adipose tissue development
57. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
58. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro
59. Inhibition of adipogenesis by a COOH-terminally truncated mutant of PPARγ2 in 3T3-L1 cells
60. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis J
61. A PPARγ mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus
62. PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene
63. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter
64. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
65. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators
66. Regulation of FAT/CD36 gene expression: Further evidence in support of a role of the protein in fatty acid binding/transport
67. Peroxisome proliferator-activated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP1, UCP2, UCP3) gene expression
68. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes
69. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma
70. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance
71. Tumor necrosis factor alpha inhibits signaling from the insulin receptor
72. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance
73. TNF-alpha induced insulin resistance in vivo and its prevention by troglitazone
74. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling
75. Thiazolidinediones and insulin resistance: Peroxisome proliferator-activated receptor gamma activation stimulates expression of the CAP gene
76. Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene
77. Thiazolidinediones (PPARγ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes
78. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome
79. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress
80. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice
81. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
82. Induction of Acrp30 levels by PPARγ agonists: A potential mechanism of insulin sensitization
83. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients
84. Adipose tissue is required for the antidiabetic, but not the hypolipidemic, effect of thiazolidinediones
85. Role of skeletal muscle in thiazolidinedione insulin sensitizer action
86. An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissue
87. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues
88. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability
89. The hormone resistin links obesity to diabetes
90. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
91. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
92. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
93. Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to LPS in vitro or in vivo
94. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
95. A novel therapy for colitis utilizing PPARγ ligands to inhibit the epithelial inflammatory response
96. PPARγ induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A
97. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
98. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma
99. Terminal differentiation of human breast cancer through PPARγ
100. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
101. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers
102. Differentiation and reversal of malignant changes in colon cancer through PPARγ
103. Activators of the nuclear receptor PPARγ enhance colon polyp formation
104. + mice
105. Etiology and prevalence of hypertension in diabetic patients
106. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
107. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
108. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
109. Molecular scanning of the human peroxisome proliferator activated receptor γ gene in diabetic Caucasians: Identification of a Pro12Ala PPARγ 2 missense mutation
110. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
111. A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans
112. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor γ2 gene with obesity in two Caucasian populations
113. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of Type 2 diabetes
114. Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men
115. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus
116. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ
117. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus, and hypertension
118. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
119. Fatty acids activate the clofibric acid activated receptor and the glucocorticoid receptor
120. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans
121. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor
122. Differential expression of peroxisome proliferator-activated receptor (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
123. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptorα in humans
124. Expression of peroxisome proliferator-activated receptor alpha (PPARα) in primary cultures of human vascular endothelial cells
125. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
126. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
127. Peroxisome proliferator activated receptor-alpha expression in human liver
128. Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter
129. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner
130. The mouse peroxisome-proliferator-activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene
131. Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression
132. Characterization of protein-DNA interactions within the peroxisome proliferator-responsive element of the rat hydratase-dehydrogenase gene
133. Co-ordinate induction of hepatic mitochondrial and peroxisomal carnitine acyltransferase synthesis by diet and drugs
134. Co-regulation of tissue-specific alternative human carnitine palmitoyltransferase Ibeta gene promoters by fatty acid enzyme substrate
135. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor
136. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha
137. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARα)
138. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression
139. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids
140. Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription
141. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes
142. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators
143. Emerging concepts in metabolic abnormalities associated with coronary artery disease
144. Distribution of lipids in 8,500 men with coronary artery disease
145. Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk
146. Conclusions from the VA-HIT study
147. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal Acyl Co-enzyme A oxidase
148. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice
149. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
150. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
151. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
152. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
153. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators
154. PPARγ and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
155. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
156. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and non-diabetic low density lipoprotein receptor-deficient mice
157. Peroxisome proliferator- activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
158. Troglitazone inhibits atherosclerosis in apoliporotein E-knockout mice
159. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits
160. The PPARα-leukotriene B4 pathway to inflammation control
161. Induction of IκBα expression as a mechanism contributing to the antiinflammatory activities of peroxisome proliferator-activated receptor-alpha activators
162. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia
163. Peroxisome proliferator activated receptors: Structures and function
164. Variation in the PPARa gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects
165. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acid
166. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
167. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators
168. Assignment of the human nuclear hormone receptor, NUC1 (PPARδ), to chromosome 6p21.1-p21.2
169. Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes
170. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors
171. Multiple female reproductive failure in cyclooxygenase 2-deficient mice
172. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ
173. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
174. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells
175. Regional distribution of PPARβ in the cerebellum of the rat
176. Rat PPARδ contains a CGG triplet repeat and is prominently expressed in the thalamic nuclei
177. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development
178. Neurons in the thalamic cm-pf complex supply striatal neurons with information about behaviorally significant sensory events
179. Hypothalamic neuronal loss and altered circadian rhythm of temperature in a rat model of mesial temporal lobe epilepsy
180. Member of the peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes
181. PPARδ agonists stimulate oligodendrocyte differentiation in tissue culture
182. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ)
183. Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures